A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy

A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy

Immunotherapies have recently gained traction as highly effective therapies in a subset of late-stage cancers. Unfortunately, only a minority of patients experience the remarkable benefits of immunotherapies, whilst others fail to respond or even come to harm through immune-related adverse events. F...

Full description

Bibliographic Details
Main Authors: Ceiler, J. (Author), Christopoulos, P. (Author), Daniel-Moreno, A. (Author), Elshiaty, M. (Author), Ferry, Q. (Author), Feufel, J. (Author), Heuvelman, M. (Author), Hinkfoth, F. (Author), Hofmann, S. (Author), Horos, R. (Author), Jehn, J. (Author), Kahraman, M. (Author), Kittner, P. (Author), Lusky, F. (Author), Mercaldo, N. (Author), Muley, T. (Author), Nötzel, D. (Author), Pelea, O. (Author), Rabe, K.F (Author), Rajakumar, T. (Author), Reck, M. (Author), Sauka-Spengler, T. (Author), Schenz, J. (Author), Schindler, H. (Author), Sikosek, T. (Author), Skottke, J. (Author), Steinkraus, B.R (Author), Thomas, M. (Author), Tikk, K. (Author), Uhle, F. (Author), Uhle, S. (Author), Weigand, M.A (Author), Wu, Q. (Author)
Format: Article
Language:English
Published: Nature Research 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items